

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 February 2022 (10.02.2022)



(10) International Publication Number
WO 2022/032288 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2021/071109

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
05 August 2021 (05.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/061,676 05 August 2020 (05.08.2020) US
63/074,779 04 September 2020 (04.09.2020) US

(71) Applicant: **DICERNA PHARMACEUTICALS, INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: **BROWN, Bob Dale**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **DUDEK, Henryk T.**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **ABRAMS, Marc**; c/o Dicerna Pharmaceuti-
cals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **HAN, Wen**; c/o Dicerna Pharmaceuticals, Inc.,
75 Hayden Avenue, Lexington, Massachusetts 02421 (US).
TURANOV, Anton; c/o Dicerna Pharmaceuticals, Inc., 75
Hayden Avenue, Lexington, Massachusetts 02421 (US).

(74) Agent: **REID, Andrea L.C.** et al.; c/o Dechert LLP, One
International Place, 40th Floor, 100 Oliver Street, Boston,
Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING *LPA* EXPRESSION

(57) Abstract: Oligonucleotides are provided herein that inhibit apolipoprotein(a) (*LPA*) expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with *LPA* expression.

WO 2022/032288 A1